Literature DB >> 26478757

Measurement of ADAMTS13.

Han-Mou Tsai1.   

Abstract

ADAMTS13, encoded on chromosome 9q34, is a member of the ADAMTS (a disintegrin and metalloprotease with thrombospondin type 1 motif) metalloprotease family, containing the common domain structure of (from the amino terminus) signal peptide, propeptide, reprolysin type metalloprotease, thrombospondin type 1 motif, cysteine-rich region, and spacer domain. ADAMTS13 cleaves von Willebrand factor (VWF) in a shear stress dependent manner. Deficiency of the enzyme causes the platelet aggregation of thrombotic thrombocytopenic purpura (TTP). Inhibitory antibodies of ADAMTS13 are detected in patients with acquired TTP, while homozygous or double heterozygous mutations of the ADAMTS13 gene cause the hereditary form of the disease 1. Targeting of the ADAMTS13 gene by recombinant technology has reproduced the phenotype of human TTP in ADAMTS13-null mice 2. Despite these advances, intense controversy and confusion persist regarding the role of ADAMTS13 assays in the diagnosis of TTP. This brief review highlights some of the contentious issues and proposes steps to improve the diagnostic value of ADAMTS13 assays.

Entities:  

Year:  2006        PMID: 26478757      PMCID: PMC4605609     

Source DB:  PubMed          Journal:  Int Rev Thromb        ISSN: 1880-8549


  26 in total

1.  Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP)

Authors:  H E Gerritsen; P L Turecek; H P Schwarz; B Lämmle; M Furlan
Journal:  Thromb Haemost       Date:  1999-11       Impact factor: 5.249

2.  Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.

Authors:  S G Shelat; P Smith; J Ai; X L Zheng
Journal:  J Thromb Haemost       Date:  2006-08       Impact factor: 5.824

Review 3.  Thrombotic thrombocytopenic purpura: a review.

Authors:  R M Bukowski
Journal:  Prog Hemost Thromb       Date:  1982

4.  The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency.

Authors:  D R Terrell; L A Williams; S K Vesely; B Lämmle; J A K Hovinga; J N George
Journal:  J Thromb Haemost       Date:  2005-07       Impact factor: 5.824

5.  Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.

Authors:  A Veyradier; B Obert; A Houllier; D Meyer; J P Girma
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

6.  A rapid enzyme-linked assay for ADAMTS-13.

Authors:  J-J Wu; K Fujikawa; E C Lian; B A McMullen; J D Kulman; D W Chung
Journal:  J Thromb Haemost       Date:  2006-01       Impact factor: 5.824

7.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

8.  ADAMTS-13 activity in plasma is rapidly measured by a new ELISA method that uses recombinant VWF-A2 domain as substrate.

Authors:  J L Whitelock; L Nolasco; A Bernardo; J Moake; J-F Dong; M A Cruz
Journal:  J Thromb Haemost       Date:  2004-03       Impact factor: 5.824

9.  von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience.

Authors:  Johanna A Kremer Hovinga; Jan-Dirk Studt; Lorenzo Alberio; Bernhard Lämmle
Journal:  Semin Hematol       Date:  2004-01       Impact factor: 3.851

10.  ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases.

Authors:  Manfred Rieger; Pier Mannuccio Mannucci; Johanna A Kremer Hovinga; Andrea Herzog; Gabi Gerstenbauer; Christian Konetschny; Klaus Zimmermann; Inge Scharrer; Flora Peyvandi; Miriam Galbusera; Giuseppe Remuzzi; Martina Böhm; Barbara Plaimauer; Bernhard Lämmle; Friedrich Scheiflinger
Journal:  Blood       Date:  2005-05-12       Impact factor: 22.113

View more
  1 in total

1.  Treatment of Concurrent Thrombotic Thrombocytopenic Purpura and Graves' Disease: A Report on Two Cases.

Authors:  Karl Lhotta; Emanuel Zitt; Hannelore Sprenger-Mähr; Lorin Loacker; Alexander Becherer
Journal:  Case Rep Endocrinol       Date:  2018-08-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.